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The motion for debate was, ‘Extended follow-up of breast
cancer patients in clinic wastes time for both patients and
doctors’. Professor Mike Dixon spoke for the motion and
Professor David Cameron spoke against it. Before the debate
the delegates were asked to vote on the motion. This pre-
debate vote revealed that 30 were in agreement with the
motion, 36 disagreed and 13 were uncertain.
Speaking for the motion, Professor Dixon made the point that
there is considerable discrepancy between the recommen-
dations for follow-up from the UK and North America. He
identified that there was no evidence base to guide the
decision making, and hence follow-up had largely evolved on
an ad hoc basis. Equally, there was no evidence that screen-
ing for distant metastases at follow-up clinics was of any
value. Therefore, the main aims of follow-up would be to
detect local or regional recurrence and perhaps to monitor for
psychological morbidity. Potential methods for detecting such
recurrences would include clinical examination at a follow-up
clinic, mammography and the patient herself detecting an
abnormality. He also highlighted that routine clinical
examination at follow-up was of little value but accepted that
mammographic surveillance was helpful. His
recommendations were therefore that hospital follow-up is
reasonable for the first 1 to 2 years after surgery, and there-
after surveillance should be by annual mammography and an
annual questionnaire. This should be combined with dis-
charge of the patient back to primary care.
Speaking against the motion, Professor Cameron also made
the point that follow-up policy varied markedly between the
UK and North America. He too agreed that there was no
clinical trial evidence of the effect on outcome of a policy of
regular follow-up versus no follow-up. He also emphasized
strongly that detailed outcome information is mandatory for all
patients enrolled in clinical trials, and that such information is
best accrued through regular follow-up. The need to monitor
side effects of treatment, especially in relation to some of the
more recently introduced therapies such as aromatase inhibi-
tors (bone health) and trastuzumab (cardiac toxicity), was
another important reason for maintaining longer follow-up.
Additionally, patients find routine follow-up reassuring, and in
one study 15% of patients requested review at the clinic
during the year immediately after their discharge. Finally,
Professor Cameron commented that discontinuing regular
follow-up might not improve health economics, because the
treatment of recurrence following delayed detection would be
considerably more expensive than treatment of recurrence
detected at an earlier stage. Similarly, treatment of osteo-
porosis-related fractures would be considerably more
expensive than the medical management of early-stage osteo-
porosis detected through regular follow-up.
During the debate it became clear that both speakers felt that
some form of follow-up was essential, and it was only on the
question of methodology that they disagreed. Neither speaker
defined ‘extended’, which clearly is of relevance.
Immediately after the debate the audience members were
asked to vote on the motion again. On the second vote 32
agreed with the motion, 44 disagreed and three remained
uncertain.
After the debate, the delegates were also asked to complete
a questionnaire comprising five questions on various aspects
of follow-up. The first question related to follow-up frequency.
Only 11.4% supported a follow-up duration of 2 years or less.
The majority (35.7%) felt that follow-up should continue for as
long as the patient requested. The second question probed
the primary reasons for follow-up. Of the participants, 52.7%
felt that every reason given was important - to check for
recurrence, to ameliorate symptoms, clinical trial protocols
and to reassure patients. The most important reason for two
participants was to provide the treating physician with
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reassurance. The third question was, ‘Is follow-up beyond
2 years best done by primary care physicians?’; this was
deemed inappropriate by 82% of respondents. The fourth
question was, ‘Does routine follow-up require senior medical
staff?’; a total of 59.2% felt that this was not necessary. The
final question was, ‘Should follow-up be decided on an
individual patient basis?’; a total of 92% felt that this was an
appropriate approach.
From the evidence presented in the debate, the result of the
votes and the results of the questionnaire, there is little doubt
that there is general agreement that follow-up is essential and
that this should be hospital based rather than through primary
care. The major advantages of follow-up include the acqui-
sition of outcome data, particularly in relation to clinical trials.
Early detection of local or regional recurrence is important and
is probably best monitored with regular mammography. The
monitoring of side effects of treatment is important, particularly
in relation to the early detection of preventable complications
of such treatment. Total length of follow-up should certainly
exceed 2 years, and ideally it should be patient centred and,
where appropriate, individualized.
These views are at variance with both North American
guidelines and the guidelines issued by the National Institute
for Health and Clinical Excellence. They also raise the
question of whether certain aspects of follow-up policy are
suitable for study within the context of a prospective clinical
trial. Furthermore, they raise questions regarding follow-up
methodology in terms of nurse-led follow-up clinics, perhaps
for those patients at low risk for recurrence, and more focused
medical follow-up of those at high risk for recurrence.
Perhaps this debate will encourage us all to examine our own
practice in the hope that new and more appropriate follow-up
policies can be developed.
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